CytomX Therapeutics, Inc. (NASDAQ:CTMX)‘s stock had its “outperform” rating reiterated by equities researchers at Cowen and Company in a report issued on Thursday.

A number of other analysts have also issued reports on CTMX. BidaskClub raised CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. Nomura lifted their target price on CytomX Therapeutics to $44.00 and gave the stock a “buy” rating in a research report on Wednesday. Bank of America Corporation reaffirmed a “buy” rating and set a $30.00 target price (up from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday, August 8th. Finally, Wedbush reaffirmed an “outperform” rating and set a $37.00 target price (up from $26.00) on shares of CytomX Therapeutics in a research report on Wednesday. Two analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company’s stock. CytomX Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $32.67.

CytomX Therapeutics (NASDAQ CTMX) traded down 1.99% on Thursday, hitting $22.63. The stock had a trading volume of 142,679 shares. The stock’s market cap is $834.30 million. The company’s 50-day moving average is $16.92 and its 200-day moving average is $15.62. CytomX Therapeutics has a one year low of $9.85 and a one year high of $24.67.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. The business had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. On average, analysts anticipate that CytomX Therapeutics will post ($1.49) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2017/10/05/cytomx-therapeutics-inc-ctmx-receives-outperform-rating-from-cowen-and-company.html.

In related news, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction dated Wednesday, August 9th. The stock was sold at an average price of $15.00, for a total value of $37,500.00. Following the completion of the sale, the chief financial officer now directly owns 19,626 shares of the company’s stock, valued at $294,390. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Frederick W. Gluck sold 5,000 shares of the business’s stock in a transaction dated Tuesday, September 26th. The shares were sold at an average price of $17.30, for a total value of $86,500.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 100,306 shares of company stock valued at $1,924,746. 4.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its holdings in CytomX Therapeutics by 1.3% in the second quarter. Russell Investments Group Ltd. now owns 22,134 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 292 shares during the last quarter. American International Group Inc. increased its holdings in CytomX Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 12,580 shares of the biotechnology company’s stock valued at $217,000 after buying an additional 834 shares during the last quarter. Legal & General Group Plc increased its holdings in CytomX Therapeutics by 28.6% in the second quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 1,434 shares during the last quarter. Teachers Advisors LLC increased its holdings in CytomX Therapeutics by 6.7% in the fourth quarter. Teachers Advisors LLC now owns 34,961 shares of the biotechnology company’s stock valued at $384,000 after buying an additional 2,209 shares during the last quarter. Finally, Swiss National Bank increased its holdings in CytomX Therapeutics by 19.1% in the first quarter. Swiss National Bank now owns 26,800 shares of the biotechnology company’s stock valued at $463,000 after buying an additional 4,300 shares during the last quarter. 59.97% of the stock is owned by hedge funds and other institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.